The Competition Commission of India (CCI) approves (a) acquisition of majority shareholding in Optimus Drugs Private Limited (ODPL) by Sekhmet Pharmaventures Private Limited (Sekhmet); and (b) ODPL’s acquisition of shareholding in Optimus Pharma Private Limited (OPPL) and Optimus Life Science Private Limited (OLSPL) under Section 31(1) of the Competition Act, 2002.
Sekhmet is a private company engaged in providing management services to its subsidiary, Anjan Drugs Private Limited (Anjan). Anjan is engaged in the manufacture and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in India and abroad. Sekhmet ultimately belongs to the PAG group, a group that is a leading alternative investment firm focused on APAC, with a combination of three core strategies – Credit & Markets, Private Equity and Real Assets.
Targets
ODPL is engaged in the manufacture and sale of APIs and pharmaceutical intermediates in India.
OPPL is engaged in the manufacture and sale of finished dosage formulations (FDFs), as well as providing contract development and manufacturing (CDMO) services for FDFs in India.
OLSPL is engaged in the marketing of FDFs for its group companies in India.
Social media is bold.
Social media is young.
Social media raises questions.
Social media is not satisfied with an answer.
Social media looks at the big picture.
Social media is interested in every detail.
social media is curious.
Social media is free.
Social media is irreplaceable.
But never irrelevant.
Social media is you.
(With input from news agency language)
If you like this story, share it with a friend!
We are a non-profit organization. Help us financially to keep our journalism free from government and corporate pressure
0 Comments